New research confirms Lutetium-177-PSMA-617 is effective for advanced prostate cancer, even after Radium-223 treatment.

Lutetium-177 (Lu-177) Market is Segmented by Type (Non-carrier-added, Carrier-added), by Application (Nuclear Therapy, Others). The Lutetium-177 market is poised for significant expansion as ...

Lutetium-177 (Lu-177) market is Segmented by Type (Non-carrier-added, Carrier-added), by Application (Nuclear Therapy, Others). BANGALORE, India, Feb. 18, 2025 ...

Market is Segmented by Type (Non-carrier-added, Carrier-added), by Application (Nuclear Therapy, Others). BANGALORE, India, Feb. 18, 2025 /PRNewswire/ -- The Global ...

Prostate cancer poses significant challenges for many patients. Radioligand therapies have offered hope by targeting cancer cells with precision. While Lutetium-177 therapy has been effective for many ...

Using an ARPI or taxane after 177Lu-PSMA-617 can produce a robust PSA response in patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu-PSMA-617) was approved in 2022 for patients with metastatic ...

Real-world data support trial data on the use of lutetium-177 PSMA-617 in patients with PSMA-positive, metastatic castration-resistant prostate cancer.

Baseline fracture risk for prostate cancer patients initiating long-term androgen deprivation therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...

Called the Qinshan Nuclear Power Base plant, it has already produced its first batch of Lutetium-177 (Lu-177) medical isotopes. The plant opened for business on December 26 and uses online ...

Efficacy outcomes 12 months after initiation of darolutamide in non-metastatic castrate resistant prostate cancer (nmCRPC) from the real world UK multi-centre RECORD study. Real-world clinical ...

It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify patients for whom PSMA-targeted therapy with (177 Lu)lutetium vipivotide ...

68 Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177 Lu-PSMA617 in 8 patients with PSA decline ? 98 percent in a prospective phase II study. Any disease ...